Analyst consensus rating
Context Therapeutics Analyst Rating: none
Direct answer
Context Therapeutics's consensus rating is none.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.03.
Forecast evidence checked October 18, 2026.
Get free Context Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.24
- Average price target
- $4.03
- High price target
- $5.00
- Low price target
- $2.00
- Low target gap
- +719.7%
- Target upside
- +1,552.7%
- High target gap
- +1,949.2%
- Target range width
- 1,229.5%
- Consensus rating
- none
- Analysts
- 8
- Evidence date
- October 18, 2026
- Valid through
- October 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Context Therapeutics?
Context Therapeutics has a verified none consensus. The same dataset has an average price target of $4.03.
How far are Context Therapeutics's low and high targets from the recorded price?
The low target implies +719.7%, while the high target implies +1,949.2%.
How many analysts are included in Context Therapeutics's consensus?
The verified consensus includes 8 analysts.
How is Context Therapeutics's target upside or downside calculated?
The average target of $4.03 is divided by the recorded price of $0.24, then one is subtracted to produce +1,552.7%. This does not guarantee a future return.
When was Context Therapeutics's analyst forecast verified?
The data was verified on 2026-10-18. The dataset is valid through 2026-10-25.